Navigation Links
Luminex Corporation Second Quarter Earnings Release Scheduled for July 29, 2013
Date:7/9/2013

AUSTIN, Texas, July 8, 2013 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced that it expects to report results for the second quarter of 2013 on Monday, July 29, 2013 after the close of trading.

(Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO)

Management will hold a conference call to discuss the operating highlights and financial results for the second quarter ended June 30, 2013 on July 29, 2013, at 5:00 p.m. Eastern time.

The conference call will be webcast live and will be accompanied by a slide presentation, both of which may be accessed at Luminex Corporation's website at http://www.luminexcorp.com. Simply log on to the website, go to the About Us section and access the Investor Relations link. Please go to the website at least 15 minutes prior to the call to register, download and install any necessary audio/video software. If you are unable to participate during the live webcast, the call and slides will be archived for six months on the website using the 'replay' link.

The use of pop-up blocking software may impair your ability to view webcasts. If you use this software, press and hold the CTRL key when you click on the Register button. Please contact your IT group if you are unable to override this feature. Unauthorized recording or downloading of this event is not permitted.

About Luminex Corporation

Luminex is committed to applying its passion for innovation toward advancing healthcare and research worldwide. The Company is transforming global healthcare and life-science research through the development, manufacturing and marketing of proprietary instruments and assays utilizing xMAP® open-architecture, multi-analyte platform and MultiCode® real-time polymerase chain reaction (PCR) and multiplex PCR-based technologies, that deliver cost-effective and rapid results to clinicians and researchers. Luminex's technology is commercially available worldwide and in use in leading clinical laboratories as well as major pharmaceutical, diagnostic, biotechnology and life-science companies. The Company is meeting the needs of customers in markets as diverse as clinical diagnostics, pharmaceutical drug discovery, biomedical research including genomic and proteomic research, personalized medicine, bio-defense research and food safety. For further information on Luminex Corporation and the latest advances in multiplexing using award winning technology, please visit http://www.luminexcorp.com.

Statements made in this release that express Luminex Corporation's or management's intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements. The words "believe," "expect," "intend," "estimate," "anticipate," "will," "could," "should" and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company's actual results or performance could differ materially from those anticipated or projected in such forward-looking statements. Factors that could cause Luminex's actual results or performance to differ materially include risks and uncertainties relating to, among others, market demand and acceptance of Luminex's products, the Company's dependence on strategic partners for development, commercialization and distribution of products, concentration of the Company's revenue in a limited number of strategic partners, fluctuations in quarterly results due to a lengthy and unpredictable sales cycle and bulk purchases of consumables, Luminex's ability to scale manufacturing operations and manage operating expenses, gross margins and inventory levels, potential shortages of components, competition, the timing of regulatory approvals, the implementation, including any modification, of the Company's strategic operating plans, risks and uncertainties associated with implementing our acquisition strategy and the ability to integrate acquired companies or selected assets into our consolidated business operations, as well as the risks discussed under the heading "Risk Factors" in Luminex's Reports on Forms 10-K and 10-Q, as filed with the Securities and Exchange Commission. The forward-looking statements contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in Luminex's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Luminex Corporate Contact:
Harriss T. Currie
Chief Financial Officer and Vice President, Finance
512-219-8020
hcurrie@luminexcorp.com

 

Luminex Investor Relations Contact:
Matthew D. Scalo
Sr. Director of Investor Relations
512-219-8020
mscalo@luminexcorp.com


'/>"/>
SOURCE Luminex Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Natural Molecular Testing Corporation Launches an Expanded Personalized Medicine Panel Built on Luminex Corporations xMAP Technology
2. Luminex Corporation and EMD Millipore Extend Their Global Supply and Distribution Agreement
3. Luminex Corporation To Present At Upcoming Investment Conferences
4. Luminex Corporation Reports First Quarter 2013 Results
5. Luminex Corporation First Quarter Earnings Release Scheduled for April 29, 2013
6. Luminex Corporation Reports Fourth Quarter And Full Year 2012 Results
7. Luminex Corporation To Present At Leerink Swann Global Healthcare Conference
8. Luminex Corporation Reports Third Quarter 2012 Results
9. Luminex Corporation To Present At Upcoming Investment Conferences In September
10. Luminex Corporation Hosts 10th Annual Planet xMAP Symposium in Monaco
11. Luminex Corporation Recognized as Best Technology Company in Austin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... SAN FRANCISCO , Feb. 11, 2016  Kindred ... focused on saving and improving the lives of pets, ... Technical Section of the New Animal Drug Application (NADA) ... the pivotal field study (KB0120) of Zimeta for the ... by the Company. --> ...
(Date:2/11/2016)... Potrero Medical, Inc., the developer of the Accuryn™ critical care ... George M. Rapier, III , MD, to its Board of ... is one of the nation,s largest physician owned practice management ... Texas and Florida . ... medicine practice, he has been instrumental to the company,s growth ...
(Date:2/11/2016)... , Feb. 11, 2016  AfterPill.com is reporting ... recommend alcohol abstinence for all women who are at ... the U.S. each year and raises the risks of ... --> According to the Guttmacher Institute, ... of women of child-bearing age, who have sex without ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... February 12, 2016 , ... Mediaplanet today announces ... The print component of “Revolutionizing Cancer Care” is distributed within the February 12 ... Seattle, with a circulation of approximately 250,000 copies and an estimated readership of ...
(Date:2/12/2016)... ... February 12, 2016 , ... US Sport Camps is pleased to announce ... located in Norwalk, serves as the host site and directing the camps is PGA ... have had successful camps in recent years around Des Moines and are fortunate to ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... in the field of long term care. With that, says Patrick Loughney, president ... professionals in administrative roles in long term care environments. His company, which offers ...
(Date:2/12/2016)... ... ... the exception of restorative dentistry, to date there has been no other option in the ... FDA, there is a now a new protocol in stopping cavity progression; Silver Diamine Fluoride ... to apply. The application is as simple as drying the tooth and applying the ...
(Date:2/11/2016)... ... , ... According to an article published February 1st on Consumer ... is being recalled due to the discovery that it contains dangerous adulterants. According to ... supplement on the market proven to help people safety lose excess weight, such cases ...
Breaking Medicine News(10 mins):